Carcinoma, Renal Cell
7 competing products in clinical development for Carcinoma, Renal Cell.
Pipeline by Phase
Phase 13
Phase 34
All Products (7)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Belzutifan + Lenvatinib + Cabozantinib | Eisai | Phase 3 | Active | 44 |
| Pembrolizumab + Belzutifan + Pembrolizumab/Quavonlimab + Lenvatinib | Eisai | Phase 3 | Active | 44 |
| Pembrolizumab + Belzutifan + Pembrolizumab/Quavonlimab + Lenvatinib | Eisai | Phase 3 | Active | 44 |
| Atezolizumab + Cabozantinib | Chugai Pharmaceutical | Phase 3 | Terminated | 32 |
| AGS-16C3F | Astellas Pharma | Phase 1 | Completed | 29 |
| Lenvatinib + Everolimus | Eisai | Phase 1 | Completed | 29 |
| AGS-16M18 | Astellas Pharma | Phase 1 | Terminated | 21 |